BUŠÁNYOVÁ, Beáta - VAJTER, Marie - KELIFOVÁ, Silvie - LIŠKOVÁ, Petra - MIKOVÁ, Hedviga - BRECIKOVÁ, Katarína - ŽIGMOND, Ján - ROGALEWICZ, Vladimír - TICHOPÁD, Aleš - VIŠŇANSKÝ, Martin - ŠARKANOVÁ, Ivana. Leber hereditary optic neuropathy in Czechia and Slovakia: Quality of life and costs from patient perspective. In: Heliyon. 2024. ISSN 2405-8440, Vol. 10, no. 11 (2024), art. no. e32296, p. [1-8]
(2024: 3.400 - IF, 3.900 - IF 5y, 0.627 - SJR, Q1 - SJR Best Q, Q2 - JCR Best Q)

HAWLINA, Marko - KOVAČ, Lea - BRECIKOVÁ, Katarína - ŽIGMOND, Ján - ROGALEWICZ, Vladimír - TICHOPÁD, Aleš - VIŠŇANSKÝ, Martin - ŠARKANOVÁ, Ivana. Leber hereditary optic neuropathy in Slovenia: quality of life and costs from patient perspective. In: Orphanet journal of rare diseases. 2024. ISSN 1750-1172, Vol. 19, no. 1 (2024), art. no. 318, p. [1-6]
(2024: 3.500 - IF, 4.000 - IF 5y, 1.269 - SJR, Q1 - SJR Best Q, Q2 - JCR Best Q)

BUCEK PŠENKOVÁ, Mária - HLAVINKOVÁ, Lucia - VIŠŇANSKÝ, Martin - GREGA, Dominik - ONDRUŠOVÁ, Martina. The checklist for standard methodological requirements and reporting of economic evaluation of medicines in Slovakia. In: Value in Health Regional Issues. 2024. ISSN 2212-1099, Vol. 39, no. (2024), p. 14-19.
(2024: 1.500 - IF, 1.700 - IF 5y, 0.626 - SJR, Q1 - SJR Best Q, Q3 - JCR Best Q)

GREGA, Dominik - KOLÁŘ, Jozef - VIŠŇANSKÝ, Martin. Average CET limit: Is it possible to introduce a single CET for the whole EEA?. In: ISPOR Europe. Value In Health. 2022. 2022. ISSN 1098-3015, Vol. 25, no. 12, suppl. (2022), p. 557.
(2022: 4.500 - IF, 124 - H-index, 6.200 - IF 5y, 1.414 - SJR, Q1 - SJR Best Q, Q1 - JCR Best Q)

VIŠŇANSKÝ, Martin - BUTALOVÁ, Anna. Impact of the international reference pricing on access to standard therapy drugs for copd [Dopad medzinárodného referencovania cien na dostupnosť štandardnej terapie pre liečbu CHOCHP]. In: ISPOR Europe 2018-New perspectives for improving 21st century health systems. Value In Health. 2018. 2018. ISSN 1098-3015, Vol. 21, suppl. 3 (2018), p. 415-416.
(2018: 5.037 - IF, 97 - H-index, 6.131 - IF 5y, 1.836 - SJR, Q1 - SJR Best Q, Q1 - JCR Best Q)

VIŠŇANSKÝ, Martin. Is transparency in slovak hta efficient enought? Comparing pharmacoeconomics methodologies used in pricing & reimbursement applications for innovative therapies towards requirements defined by the law [Je hodnotenie zdravotníckych technológii na Slovensku dostatočne transparentne? Porovnanie farmakoekonomických metód, používaných pri podaní žiadostí o cenu a úhradu pre inovatívne lieky v porovnaní s požiadavkami zákona]. In: ISPOR Europe 2018-New perspectives for improving 21st century health systems. Value In Health. 2018. 2018. ISSN 1098-3015, Vol. 21, suppl. 3 (2018), p. 318.
(2018: 5.037 - IF, 97 - H-index, 6.131 - IF 5y, 1.836 - SJR, Q1 - SJR Best Q, Q1 - JCR Best Q)

VIŠŇANSKÝ, Martin - KABABIKOVÁ, Diana. Impact of the international reference pricing on access to standard therapy drugs for asthma and COPD [Dopad medzinárodného referencovania cien na dostupnosť štandardnej terapie astmy a CHOCHP]. In: ISPOR : Congress. Value In Health. 2016. 2016. ISSN 1098-3015, Vol. 19, č. 7(2016), s. A560.
(2016: 3.824 - IF, 97 - H-index, 4.491 - IF 5y, 1.908 - SJR, Q1 - SJR Best Q, Q1 - JCR Best Q)

VIŠŇANSKÝ, Martin. International Reference pricing across EU [Medzinárodné referencovanie cien v EÚ]. In: ISPOR : Congress. Value In Health. 2016. 2016. ISSN 1098-3015, Vol. 19, č. 7(2016), s. A347.
(2016: 3.824 - IF, 97 - H-index, 4.491 - IF 5y, 1.908 - SJR, Q1 - SJR Best Q, Q1 - JCR Best Q)

ÁGH, Tamás - INOTAI, András - SZILBERHORN, László - CULIG, Josip - VIŠŇANSKÝ, Martin - KALÓ, Zoltán - PETROVA, Guenka. A Novel Method for Calculating Medication Adherence to Poly-Pharmacotherapy by Linking General Practice Prescribing Data and Pharmacy Dispensing Records. In: ISPOR : Congress. Value In Health. 2015. 2015. ISSN 1098-3015, Vol. 18, č. 7(2015), s. A737.
(2015: 3.824 - IF, 97 - H-index, 3.761 - IF 5y, 1.736 - SJR, Q1 - SJR Best Q, Q1 - JCR Best Q)

TOMEK, Dominik - VIŠŇANSKÝ, Martin - MARUŠÁKOVÁ, Elena. HTA Principles Inclusion in New European Union Member States [Princípy hodnotenia zdravotníckych technológií v nových členských štátoch EÚ]. In: ISPOR : Congress. Value In Health. 2012. 2012. ISSN 1098-3015, Vol. 15, č. 7(2012), s. A319.
(2012: 2.191 - IF, 97 - H-index, 2.903 - IF 5y, 1.417 - SJR, Q1 - SJR Best Q, Q1 - JCR Best Q)